Omega Biosystems is a life science tools company developing and commercializing disruptive instruments for the cell analysis and drug discovery industries. Omega Biosystems’ fluorescence imaging optical technology is bringing the field of flow cytometry into the next generation. This technology directly addresses a major shortcoming in flow cytometry: data acquisition speed. Omega Biosystems enables flow cytometry to operate at throughputs compatible for widespread use in the drug discovery and screening industry. As a result, researchers are able to screen compounds more effectively and cheaply, enabling more drugs to reach the market sooner.
Graduated in 2017
Omega Biosystems was acquired by Becton, Dickinson and Company (BD) in February 2017.